Stock Taper
BFRIW
BIOFRONTERA INC.
NASDAQ
$0.02
▼ DOWN 2.91% (-0.00)

KEY STATISTICS

Market Cap$11.38 M
52w High$0.10
52w Low$0.02
Dividend Yield
Frequency
P/E-0.03
Volume3
Shares Out.10.87M

COMPANY

LEADERSHIP

Hermann Luebbert
CHIEF EXECUTIVE
Hermann Luebbert

COMPENSATION 2026

Salary$470,500
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$3,879
Total$733,225

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 29, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
92

UPCOMING EARNINGS

DateNov 18, 2026
DayWednesday
Rev. Est.$8.25M
NOV
18
WED

PRICE

$0.02 ▼ DOWN 2.91% (−$0.00)
$0.02$0.02$0.02$0.02$0.02$0.02$0.02$0.02$0.029:40 AM10:05 AM10:29 AM10:54 AM11:19 AM11:43 AM12:08 PM0.02

About Biofrontera Inc.

https://www.biofrontera-us.com ↗

Biofrontera Inc. is a biopharmaceutical company based in Woburn, MA, specializing in dermatological treatments like Ameluz for actinic keratosis and Xepi for impetigo in the U.S.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT BIOFRONTERA INC. IS KNOWN FOR

Ameluz® (aminolevulinic acid hydrochloride gel, 10%)
Ameluz® (aminolevulinic acid hydrochloride gel, 10%)

Ameluz, Biofrontera Inc.'s flagship prescription gel, treats actinic keratoses using photodynamic therapy with the BF-RhodoLED® lamp, forming a key part of their dermatology-focused portfolio.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

OFFICER: CHIEF FINANCIAL OFFICER
Leffler Eugene Frederick
Purchase · 31.3K shares
2026-07-28
OFFICER: CHIEF FINANCIAL OFFICER
Leffler Eugene Frederick
Sale · 31.3K shares
2026-07-28
DIRECTOR, OFFICER: CEO & CHAIRMAN
Luebbert Hermann
Purchase · 62.5K shares
2026-07-28
DIRECTOR, OFFICER: CEO & CHAIRMAN
Luebbert Hermann
Sale · 62.5K shares
2026-07-28

SECTORS PEERS

PEERPRICE
LUCY$0.95COMPARE
ADIL$4.86COMPARE
SNOA$1.28COMPARE
SBFM$0.90COMPARE
HCWB$1.87COMPARE